A citation-based method for searching scientific literature

G G Schwartz, A G Olsson, M D Ezekowitz, P Ganz, M F Oliver, D Waters, A Zeiher, B R Chaitman, S Leslie, T Stern. JAMA 2001
Times Cited: 1858







List of co-cited articles
629 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene. N Engl J Med 2004
50

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
40

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
39

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
32

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
30

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
27

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
James A de Lemos, Michael A Blazing, Stephen D Wiviott, Eldrin F Lewis, Keith A A Fox, Harvey D White, Jean-Lucien Rouleau, Terje R Pedersen, Laura H Gardner, Robin Mukherjee,[...]. JAMA 2004
989
20

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. Circulation 2019
20

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
17

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
17

Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Konstantinos C Koskinas, Stephan Windecker, Giovanni Pedrazzini, Christian Mueller, Stéphane Cook, Christian M Matter, Olivier Muller, Jonas Häner, Baris Gencer, Carmela Crljenica,[...]. J Am Coll Cardiol 2019
63
25

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F M Sacks, M A Pfeffer, L A Moye, J L Rouleau, J D Rutherford, T G Cole, L Brown, J W Warnica, J M Arnold, C C Wun,[...]. N Engl J Med 1996
14

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Neil J Stone, Jennifer G Robinson, Alice H Lichtenstein, C Noel Bairey Merz, Conrad B Blum, Robert H Eckel, Anne C Goldberg, David Gordon, Daniel Levy, Donald M Lloyd-Jones,[...]. Circulation 2014
14


Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
John C LaRosa, Scott M Grundy, David D Waters, Charles Shear, Philip Barter, Jean-Charles Fruchart, Antonio M Gotto, Heiner Greten, John J P Kastelein, James Shepherd,[...]. N Engl J Med 2005
14


High-dose atorvastatin after stroke or transient ischemic attack.
Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan, Larry B Goldstein, Michael Hennerici, Amy E Rudolph, Henrik Sillesen, Lisa Simunovic, Michael Szarek, K M A Welch,[...]. N Engl J Med 2006
13

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Terje R Pedersen, Ole Faergeman, John J P Kastelein, Anders G Olsson, Matti J Tikkanen, Ingar Holme, Mogens Lytken Larsen, Fredrik S Bendiksen, Christina Lindahl, Michael Szarek,[...]. JAMA 2005
13

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
J Shepherd, S M Cobbe, I Ford, C G Isles, A R Lorimer, P W MacFarlane, J H McKillop, C J Packard. N Engl J Med 1995
13


Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Michael G Silverman, Brian A Ference, Kyungah Im, Stephen D Wiviott, Robert P Giugliano, Scott M Grundy, Eugene Braunwald, Marc S Sabatine. JAMA 2016
605
12

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
C Baigent, A Keech, P M Kearney, L Blackwell, G Buck, C Pollicino, A Kirby, T Sourjina, R Peto, R Collins,[...]. Lancet 2005
12

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Kausik K Ray, Christopher P Cannon, Carolyn H McCabe, Richard Cairns, Andrew M Tonkin, Frank M Sacks, Graham Jackson, Eugene Braunwald. J Am Coll Cardiol 2005
237
12

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman,[...]. J Am Coll Cardiol 2019
946
12


Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Steven E Nissen, E Murat Tuzcu, Paul Schoenhagen, B Greg Brown, Peter Ganz, Robert A Vogel, Tim Crowe, Gail Howard, Christopher J Cooper, Bruce Brodie,[...]. JAMA 2004
12

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller. Lancet 2004
11

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
538
11

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
Borja Ibanez, Stefan James, Stefan Agewall, Manuel J Antunes, Chiara Bucciarelli-Ducci, Héctor Bueno, Alida L P Caforio, Filippo Crea, John A Goudevenos, Sigrun Halvorsen,[...]. Eur Heart J 2018
11

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Steven E Nissen, Stephen J Nicholls, Ilke Sipahi, Peter Libby, Joel S Raichlen, Christie M Ballantyne, Jean Davignon, Raimund Erbel, Jean Charles Fruchart, Jean-Claude Tardif,[...]. JAMA 2006
11


Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren,[...]. N Engl J Med 2017
447
10

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, E H Barnes, M Voysey, A Gray, R Collins, C Baigent. Lancet 2012
10

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen,[...]. Eur Heart J 2016
10


Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Lars Wallentin, Richard C Becker, Andrzej Budaj, Christopher P Cannon, Håkan Emanuelsson, Claes Held, Jay Horrow, Steen Husted, Stefan James, Hugo Katus,[...]. N Engl J Med 2009
9

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Kausik K Ray, Harold E Bays, Alberico L Catapano, Narendra D Lalwani, LeAnne T Bloedon, Lulu R Sterling, Paula L Robinson, Christie M Ballantyne. N Engl J Med 2019
249
9

Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
Otavio Berwanger, Eliana Vieira Santucci, Pedro Gabriel Melo de Barros E Silva, Isabella de Andrade Jesuíno, Lucas Petri Damiani, Lilian Mazza Barbosa, Renato Hideo Nakagawa Santos, Ligia Nasi Laranjeira, Flávia de Mattos Egydio, Juliana Aparecida Borges de Oliveira,[...]. JAMA 2018
70
12

A prospective natural-history study of coronary atherosclerosis.
Gregg W Stone, Akiko Maehara, Alexandra J Lansky, Bernard de Bruyne, Ecaterina Cristea, Gary S Mintz, Roxana Mehran, John McPherson, Naim Farhat, Steven P Marso,[...]. N Engl J Med 2011
8

Interpretation of the evidence for the efficacy and safety of statin therapy.
Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets,[...]. Lancet 2016
932
8

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Patrick M Moriarty, Paul D Thompson, Christopher P Cannon, John R Guyton, Jean Bergeron, Franklin J Zieve, Eric Bruckert, Terry A Jacobson, Stephen L Kopecky, Marie T Baccara-Dinet,[...]. J Clin Lipidol 2015
301
8

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Kenichi Tsujita, Seigo Sugiyama, Hitoshi Sumida, Hideki Shimomura, Takuro Yamashita, Kenshi Yamanaga, Naohiro Komura, Kenji Sakamoto, Hideki Oka, Koichi Nakao,[...]. J Am Coll Cardiol 2015
244
8

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Marc S Sabatine, Gaetano M De Ferrari, Robert P Giugliano, Kurt Huber, Basil S Lewis, Jorge Ferreira, Julia F Kuder, Sabina A Murphy, Stephen D Wiviott, Christopher E Kurtz,[...]. Circulation 2018
131
8

Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
251
8

Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Eliano Pio Navarese, Mariusz Kowalewski, Felicita Andreotti, Marleen van Wely, Cyril Camaro, Michalina Kolodziejczak, Bartosz Gorny, Jeffrey Wirianta, Jacek Kubica, Malte Kelm,[...]. Am J Cardiol 2014
56
14

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy,[...]. N Engl J Med 2015
8

Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Marie-France Brégeault, Anthony J Dalby, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin,[...]. Circulation 2019
63
12

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
Tomas Jernberg, Pål Hasvold, Martin Henriksson, Hans Hjelm, Marcus Thuresson, Magnus Janzon. Eur Heart J 2015
403
8

Effect of two intensive statin regimens on progression of coronary disease.
Stephen J Nicholls, Christie M Ballantyne, Philip J Barter, M John Chapman, Raimund M Erbel, Peter Libby, Joel S Raichlen, Kiyoko Uno, Marilyn Borgman, Kathy Wolski,[...]. N Engl J Med 2011
533
8

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
Jordan Fulcher, Rachel O'Connell, Merryn Voysey, Jonathan Emberson, Lisa Blackwell, Borislava Mihaylova, John Simes, Rory Collins, Adrienne Kirby, Helen Colhoun,[...]. Lancet 2015
754
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.